Sidley represented ReCode Therapeutics, a clinical-stage genetic medicines company, in the closing of an extension to its Series B financing. The extension raised an additional US$50 million, for a total of US$260 million in Series B funding, from new investors that included Bioluminescence Ventures and Solasta Ventures and existing investors that included OrbiMed Advisors, AyurMaya, an affiliate of Matrix Capital Management, Leaps by Bayer, Vida Ventures, MPM Capital, EcoR1 Capital, Sanofi Ventures, and Amgen Ventures, among others. Proceeds from the financing will be used to advance ReCode’s primary ciliary dyskinesia and cystic fibrosis clinical development programs and to expand ReCode’s selective organ targeting pipeline to include mRNA and gene correction therapeutics for central nervous system, lung, liver, and musculoskeletal indications.
The Sidley team was led by James Lu (Emerging Companies and Venture Capital) and Feifei Bian (M&A and Private Equity), and included Daniel E. Gessner, Peiyu Yu, and Cyril Cutinha (M&A and Private Equity); Daniel Wei (Emerging Companies and Venture Capital); Mike Heinz (Capital Markets); and James Mendenhall (International Trade).
